2024-516870-31-00RecruitingPhase 1
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 May 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 13 Feb 2025
- Start date
- 11 Jul 2025
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Endometrial cancer, Bladder cancer, Head and neck cancer, Gastric and esophageal cancer, Cervical cancer
- EU CT number
- 2024-516870-31-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 21
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain advanced solid tumors, including endometrial, bladder, head and neck, esophageal, cervical and breast cancer. They would receive MK-8294 alone.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced solid tumors (the record does not give more detail)
Main reasons for not taking part
- Healthy volunteers cannot join
Read by machine on 9 Nov 2026.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Amsterdam | Netherlands | Recruiting |
| Radboud universitair medisch centrum Stichting | Nijmegen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.